Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). StemCell Institute's share price for the quarter that ended in Sep. 2024 was 円1672. StemCell Institute's Shares Outstanding (EOP) for the quarter that ended in Sep. 2024 was 10 Mil. Therefore, StemCell Institute's market cap for the quarter that ended in Sep. 2024 was 円17,133 Mil.
StemCell Institute's quarterly market cap
declined
from Dec. 2023 (円21,970 Mil) to Mar. 2024 (円20,351 Mil) and
declined
from Mar. 2024 (円20,351 Mil) to Sep. 2024 (円17,133 Mil).
StemCell Institute's annual market cap
increased
from Mar. 2022 (円20,571 Mil) to Mar. 2023 (円25,771 Mil) but then
declined
from Mar. 2023 (円25,771 Mil) to Mar. 2024 (円20,351 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. StemCell Institute's Enterprise Value for Today is 円11,348 Mil.
StemCell Institute Market Cap Historical Data
The historical data trend for StemCell Institute's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of StemCell Institute's Market Cap
For the Biotechnology subindustry, StemCell Institute's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
StemCell Institute's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, StemCell Institute's Market Cap distribution charts can be found below:
* The bar in red indicates where StemCell Institute's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
StemCell Institute's Market Cap for the fiscal year that ended in Mar. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
StemCell Institute (TSE:7096) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
StemCell Institute Market Cap Related Terms
Thank you for viewing the detailed overview of StemCell Institute's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
StemCell Institute is engaged in Cell bank business that separates and stores cord blood for regenerative medicine. Cord blood is the baby's blood contained in the umbilical cord and placenta that connects mother and baby. In its umbilical cord blood storage business, upon receiving notification from customers who have contracted, umbilical cord blood collected at obstetric facilities throughout Japan is collected, transported to the company's own cell processing center within 48 hours, and it provides a service to store cells at ultra-low temperature after separating cells from blood.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TSE:7096 has been successfully added to your 